糖尿病多支病变患者PCI与CABG的长期生存比较
基于瑞典SWEDEHEART登记库26,166例糖尿病多支病变患者,比较冠状动脉旁路移植术(CABG)与经皮冠状动脉介入治疗(PCI)后的死亡风险与生存时间。加权分析显示CABG全因死亡风险(HR 0.80;95%CI 0.76-0.84)和心血管死亡风险(HR 0.73;95%CI 0.68-0.78)均低于PCI,加权中位生存时间延长0.9年(95%CI 0.5-1.4),左主干或三支病变患者生存获益更大。
要点
- 糖尿病多支病变患者CABG较PCI全因死亡风险降低20%(HR 0.80)。
- CABG较PCI心血管死亡风险降低27%(HR 0.73)。
- 左主干或三支病变患者CABG生存时间延长更显著。
核心结论
- 糖尿病多支病变患者中,CABG与PCI相比全因和心血管死亡风险显著更低且加权中位生存时间更长。
- 左主干狭窄或三支病变患者中CABG的生存获益尤为明显。
研究设计与样本
- 基于瑞典SWEDEHEART登记库的全国性队列研究,纳入2006至2020年26,166例糖尿病多支病变患者。
- PCI组16,739例(64.0%),CABG组9,427例(36.0%),合并5个国家强制登记库的个体数据。
- 采用逆概率治疗加权比较组间差异,敏感性分析包括多因素Cox回归和工具变量分析,中位随访5.5年(范围0-15年)。
主要发现
- 加权全因死亡风险CABG低于PCI(HR 0.80;95%CI 0.76-0.84)。
- 加权心血管死亡风险CABG低于PCI(HR 0.73;95%CI 0.68-0.78)。
- 加权中位生存时间CABG较PCI延长0.9年(95%CI 0.5-1.4)。
- 左主干狭窄患者CABG生存时间延长4.1年(95%CI 3.3-4.9),三支病变患者延长3.4年(95%CI 2.8-4.0)。
- 瑞典19个医疗区域PCI与CABG比例差异显著,范围0.9至7.6。
关键数值与推荐
- 全因死亡风险比0.80(95%CI 0.76-0.84),心血管死亡风险比0.73(95%CI 0.68-0.78),均为CABG对比PCI。
- 加权中位生存时间差0.9年(95%CI 0.5-1.4),左主干狭窄+4.1年(95%CI 3.3-4.9),三支病变+3.4年(95%CI 2.8-4.0)。
临床怎么用
- 糖尿病合并多支病变患者选择血运重建方式时,CABG应作为优先考虑以改善长期生存。
- 左主干狭窄或三支病变的糖尿病患者从CABG中获益更大,应重点推荐。
- 区域间PCI/CABG比例差异提示需规范血运重建决策。
局限性
- 观察性登记研究,尽管采用加权和敏感性分析,仍可能存在未测量混杂。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to compare mortality risks, survival times, and regional differences after coronary artery bypass grafting or percutaneous coronary intervention in patients with diabetes and multivessel disease in a large nationwide cohort of patients. METHODS: The SWEDEHEART registry was used to identify 26,166 patients with diabetes and multivessel disease who underwent percutaneous coronary intervention (n = 16,739, 64.0%) or coronary artery bypass grafting (n = 9427, 36.0%) in Sweden from 2006 to 2020. Individual patient data from 5 mandatory national registries were merged. Inverse probability of treatment weighting was used to compare groups. Sensitivity analyses included multivariable Cox regression and instrumental variable analysis. The median follow-up time was 5.5 years (range, 0-15 years). RESULTS: Weighted all-cause mortality (hazard ratio, 0.80; 95% CI, 0.76-0.84) and cardiovascular mortality (hazard ratio, 0.73; 95% CI, 0.68-0.78) risks were lower after coronary artery bypass grafting compared with percutaneous coronary intervention. The weighted median survival time was 0.9 years longer (95% CI, 0.5-1.4) after coronary artery bypass grafting compared with percutaneous coronary intervention, with markedly longer survival found in patients with left main stem stenosis or 3-vessel disease (+4.1; 95% CI, 3.3-4.9 and +3.4; 95% CI, 2.8-4.0 years, respectively). The results of the sensitivity analyses supported the primary analysis. The percutaneous coronary intervention-to-coronary artery bypass grafting ratio varied markedly across Sweden's 19 health care regions, ranging from 0.9 to 7.6. CONCLUSIONS: Coronary artery bypass grafting was associated with significantly lower risk of all-cause and cardiovascular mortality as well as longer weighted median survival time compared with percutaneous coronary intervention in patients with diabetes and multivessel disease, particularly among patients with left main stem stenosis or 3-vessel disease.
引用
- Améen C, Hansson EC, Milojevic M, et al. Long-term survival after percutaneous coronary intervention or coronary artery bypass grafting in patients with diabetes and multivessel disease. J Thorac Cardiovasc Surg. 2026. PMID: 42285287. doi:10.1016/j.jtcvs.2026.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。